Smith & Nephew announces full commercial release of JOURNEY™ II XR Total Knee Arthroplasty

LONDONMarch 6, 2018 /PRNewswire/ — Smith & Nephew (LSE:SN, NYSE: SNN), the global medical technology business, today announces the full commercial release of bi-cruciate retaining JOURNEY II XR total knee arthroplasty (TKA) in the United States and Japan.

JOURNEY II XR is the next step in the evolution of total knee replacement surgery. By retaining, rather than substituting, the anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL), JOURNEY II XR is designed to combine the greater patient satisfaction of a partial knee replacement with the long-term survivorship and reproducible principles of TKA1-2. JOURNEY II XR accomplishes this by eliminating the past concerns of bi-cruciate retaining knees through:

  • An implant design that reflects more accurate replication of the knee anatomy3
  • A robust tibial baseplate designed for optimal fixation and fatigue strength
  • The application of Smith & Nephew’s VERILAST™ Technology, an advanced bearing surface designed to provide lasting survivorship4
  • The introduction of enabling technologies such as NAVIO™ robotics-assisted surgery and VISIONAIRE™ patient matched adaptive guides to help deliver highly reproducible outcomes

Mike Donoghue, Senior Vice President, Global Orthopaedic Marketing said, “The JOURNEY II XR knee offers surgeons an innovative treatment option for arthritic patients who have intact and well-functioning cruciate ligaments. The retention of the cruciate ligaments may provide patients with more normal feel and stability throughout the range of motion, and may lead to a smoother recovery, improved function, and better patient satisfaction.” 3,6-8

JOURNEY II total knee system is designed to achieve normal shapes, position and motion. Smith & Nephew created this platform to empower patients to “rediscover normal” following total knee arthroplasty. The full commercial release of JOURNEY II XR follows a successful limited market release in both the United States and Japan with more than 70 surgeons in both countries implanting over 1,100 JOURNEY II XR knees during the last 18 months9. Join Smith & Nephew at the American Academy of Orthopaedic Surgeons Annual Meeting, Booth #1651 in New Orleans, LAMarch 7-9 to experience the Power of Patient Satisfaction and elevate what’s possible with the JOURNEY II XR Knee system.

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

™ Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

1. Patient satisfaction after primary total and unicompartmental knee arthroplasty: an age-dependent analysis. Von Keudell, Sodha, Collins, Minas, Fitz, Gomoll; Knee. 2014 Jan;21(1):180-4. 2. Total knee replacement with retention of both cruciate ligaments: a 22-year follow-up study. P. Sabouret, F. Lavoie, J-M Cloutier Bone Joint J. 2013 Jul; 95-B(7): 917–922 3. Short-term Range of Motion is Increased after TKA with an asymmetric bicruciate stabilized implant. Accepted Poster Presentation, AAOS 2018 New Orleans. Kaitlin M. CarrollPeter K. Sculco, Brian CMichaels, Richard L. Murphy, Seth A, Jerabek, David J. Mayman 4. Testing concluded at 45 million cycles, ISO 14242-1 and 14243-3 define test completion at 5 million cycles. 5. Hommel, Hagen, and Kai Wilke. “Good Early Results Obtained with a Guided-Motion Implant for Total Knee Arthroplasty: A Consecutive Case Series.” The Open Orthopaedics Journal 11 (2017): 51–56. PMC. Web. 27 Sept. 2017. 6. Kaneko, Takao et al. Bi-cruciate substituting total knee arthroplasty improved medio-lateral instability in mid-flexion range. Journal of Orthopaedics. 14. 201-206. 10.1016 7. Grieco, Trevor F., et al. “In Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee Arthroplasty and the Normal Knee Using Fluoroscopy.” The Journal of Arthroplasty, 2017, doi:10.1016/j.arth.2017.09.035.8. Iriuchishima, Takanori, and Keinosuke Ryu. “A Comparison of Rollback Ratio between Bicruciate Substituting Total Knee Arthroplasty and Oxford Unicompartmental Knee Arthroplasty.” The Journal of Knee Surgery, 2017, doi:10.1055/s-0037-1604445. 9. Data on file with Smith & Nephew.

 

SOURCE Smith & Nephew

Related Links

http://www.smith-nephew.com

Amedica announces FDA Clearance of the Valeo C+CSC with Lumen Interbody Fusion Device

SALT LAKE CITY, UT, March 06, 2018 (GLOBE NEWSWIRE) — Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company that develops and commercializes silicon nitride as a platform for biomedical applications, is pleased to announce the U.S. Food and Drug Administration (FDA) clearance of the Valeo C+CsC with Lumen Interbody Fusion Device.

The Valeo C+CsC with Lumen Interbody Fusion Device is a composite spinal fusion implant that combines different densities of Amedica’s proprietary medical grade silicon nitride ceramic. An outer shell of solid silicon nitride is manufactured around a porous core, called CsC (Cancellous structured Ceramic). The Valeo C+CsC device is already used in Europe, and the Valeo C+CsC with Lumen is the introduction of this porous technology in the USA.

 “This FDA clearance of CsC is a significant milestone for Amedica.  CsC reflects a truly unique technology.  In addition to being the first structural porous bioceramic available in a medical implant, our published clinical data from the CASCADE clinical trial have shown that CsC can achieve spinal fusion sua sponte, i.e., in the absence of added bone grafts, and with success rates at least as favorable as bone autograft, i.e., the gold standard in bone fusion. The European device design was submitted earlier to the FDA, and the approved version is a design modification of the same material, based on feedback provided by the FDA.”  stated Dr. Sonny Bal, Chairman and Chief Executive Officer for Amedica.

“Since developing silicon nitride for spinal fusion, Amedica has investigated this highly-differentiated biomaterial platform extensively, and its most recent scientific data show that under appropriate experimental conditions, silicon nitride induces the expression of hydroxyapatite and collagen, the key constituents of bone, even in the absence of living cells.  Medical-grade titanium, and polymers like PEEK, which are widely used in spinal fusion, do not exhibit this osteoinductive property” added Dr. Bal.

“In addition to attracting new surgeon users and investigators, approval of the Valeo C+CsC with Lumen Interbody Fusion Device in the U.S. market opens the door to new designs of spinal fusion devices that may reduce or eliminate the need for added bone grafts.  In the value-based economic climate of health care today, the ability of CsC to achieve bone healing without the added expense and complexity of bone grafts is a practical advantage.  When combined with the other well-established attributes of silicon nitride, i.e., ease of viewing on every radiographic imaging modality available today, and bacteriostatic properties against a variety of bacterial species, CsC is truly without parallel among biomaterials”

Dr. Bal further stated that “beyond CsC, Amedica will continue its commitment to a strong R&D program that remains focused on developing additional key technologies related to silicon nitride.”

The Valeo C+CsC with Lumen Interbody Fusion Device is indicated for intervertebral body fusion of the cervical spine in skeletally mature patients.  Additional information about Amedica’s complete line of products can be found at www.amedica.com.

About Amedica Corporation

Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

Forward-Looking Statements 

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward looking statements include: the statement that approval of the Valeo C+CsC with Lumen Interbody Fusion Device CsC in the U.S. market opens the door to new designs of spinal fusion devices; that when combined with the other well-established attributes of silicon nitride, CsC is truly without parallel among biomaterials. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K/A, filed with the Securities and Exchange Commission (SEC) on December 27, 2017, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts:

Amedica IR
801-839-3502
IR@amedica.com

Globus Medical Enters Trauma Market

AUDUBON, Pa., March 06, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, is pleased to announce its entry into the orthopedic trauma market. Globus Medical has become a market leader in spinal device innovation, offering differentiated products and disruptive technologies in a competitive spine market, making it one of the fastest growing companies in orthopedics.  Integrating a well-known culture of speed to market and leveraging its robust product development engine, Globus Medical is poised to become a significant player in the orthopedic trauma market.

“Globus has demonstrated an unprecedented level of surgeon responsiveness resulting in the most comprehensive spinal product portfolio on the market.  We aim to continue that tradition in orthopedic trauma by leveraging a dedicated product development team with a highly trained, direct sales force to bring our innovative and efficient systems along with the best support to our surgeon and hospital customers,” said Barclay Davis, Vice President, Orthopedic Trauma.  “We feel we can capitalize on our strengths of innovation and speed to market to bring game changing technology in the trauma market.”

11 New Products FDA Cleared

Globus Medical will display its growing suite of technology solutions for trauma products this week at the American Association of Orthopaedic Surgeons’ annual meeting in New Orleans. To date, Globus has received FDA 510(k) clearance for 11 products, covering the major segments of the orthopedic trauma market – fracture plates, compression screws, cannulated screws, intramedullary nails, and external fixation.  This product portfolio is designed to treat a wide variety of fracture patterns and accommodates varying patient anatomies in the upper and lower extremities as well as hip and long bones. Each comprehensive system is optimized to streamline procedures and increase versatility, potentially reducing procedure time and expediting patient recovery.

Globus received FDA clearance for the following systems:

  • Comprehensive ANTHEM Ankle Fracture System including advanced distal Fibula plates, Cannulated Screws and key Small Fragment Plating components
  • ARBOR External Fixator System enabling fracture stabilization using one style clamp and one instrument
  • AUTOBAHN Tibial Nailing System offering both infra-patellar and supra-patellar approaches and innovative locking options
  • ANTHEM Small Fragment Plating System for general fractures with locking and non-locking implants and radiolucent instruments
  • Comprehensive ANTHEM Distal Radius Fracture System for wrist fractures that includes innovative volar, dorsal, and lateral plates as well as a robust new bridge plate
  • ANTHEM Proximal Humerus Plating System for shoulder fractures incorporating variable angle calcar screws and radiolucent instruments to simplify intra-op visualization and optimize implant placement
  • AUTOBAHN Trochanteric Nailing System for efficient geriatric hip fracture reduction and fixation
  • Comprehensive CAPTIVATE Compression Screw System for general fracture care including headless screws and an innovative variable-length family of screws for tough-to-reduce fractures or when bone purchase is limited
  • Comprehensive AUTOBAHN Femoral Nailing System with Recon screw options in both Piriformis and Troch-entry style nails
  • ANTHEM Proximal Tibia Plating System with innovative triple kick-stand screw fixation, integrated polyaxial rafting screws, and a novel radiolucent aiming arm for percutaneous fixation
  • ANTHEM Clavicle Plating System with innovative plate contours optimized for clinically-based fracture zones

“It has been impressive watching Globus move from design to development to deployment of their comprehensive trauma solutions line,” said Dr. Andrew N. Pollak, Chief of Orthopaedics at the University of Maryland Medical System. “I have been very impressed with the ability of Globus’ engineers to translate surgeon ideas and concepts into functional and easy to use implants for a wide variety of fracture patterns.”

Discover Globus Medical’s orthopedic trauma product line at the American Association of Orthopaedic Surgeons’ annual meeting in New Orleans, March 6- 11th in Booth 4371 or visit www.globusmedical.com/trauma.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Brian Kearns
Vice President, Business Development
Phone: (610) 930-1800
Email:    investors@globusmedical.com
www.globusmedical.com

Stryker Launches Next Generation Trident® II Acetabular System

MAHWAH, N.J.March 6, 2018 /PRNewswire/ — Stryker’s Joint Replacement Division today announced the commercial launch of its Trident® II Acetabular System, featuring Trident II Tritanium, at the 2018 Academy Meeting. Trident II Tritanium combines the reproducibility of Stryker’s proprietary AMagine additive manufactured Tritanium® In-Growth Technology and SOMA-verification process with the precision of Mako Robotic-Arm Assisted Surgery which enables surgeons to have a more predictable surgical experience.

Building on Stryker’s Trident brand legacy and successful clinical performance2-6, the design of Trident II Tritanium features a slim wall, enabled by additive manufacturing, that allows for large femoral head size options7 and optimal poly thickness to potentially aid in greater range of motion8, joint stability8, and lower risk of dislocation9. Its Tritanium surface is designed to mimic the complex, highly porous characteristics of cancellous bone10 to help promote long-term biologic fixation.

Additionally, Trident II shells maintain Stryker’s Innerchange™ Locking Mechanism, giving surgeons intraoperative flexibility to choose from clinically proven11-13 bearing options including: Modular Dual Mobility (MDM), X3 precisely engineered polyethylene or Trident constrained liners.

“I have trusted the clinical performance of Trident for many years, and I’m thrilled with the latest evolution of Stryker’s portfolio of acetabular implants,” said Walter B. Beaver, Jr., MD, a board-certified orthopaedic surgeon at OrthoCarolina. “With Trident II Tritanium, Stryker uses cutting-edge 3D-printing technology to uniquely address biological fixation and hip stability, which ultimately enhances my surgical experience.”14

“We’re excited to see implant design and innovative technology converge to bring important new products to market which will ultimately help make healthcare better,” said Stuart Simpson, President of Stryker’s Joint Replacement Division. “This System highlights our Trident II Tritanium shell, bringing together our leading additive manufacturing expertise, SOMA-design process and Mako Robotic-Arm Assisted Surgery System.”

Stryker’s AMagine™ Institute, its additive manufacturing innovation center in Cork, Ireland, is the largest orthopaedic implant additive manufacturing facility in the world. The company began investigating additive manufacturing technology in 2001 with academic research institutions and has since developed a state-of-the-art production process: AMagine. This latest advancement in joint replacement technology expands Stryker’s additive manufacturing implant footprint across multiple orthopaedic applications, including hip, knee and spine.

The Trident II Tritanium Acetabular System received initial 510(k) market clearance from the U.S. Food and Drug Administration in October 2016 and Trident II Tritanium Clusterhole was available through a limited market release in 2017. The full Trident II Acetabular System launching in 2018 offers five shell options: three in Tritanium (Clusterhole, Multihole or Solidback) and two Hydroxyapatite (Hemi Clusterhole or PSL Clusterhole) surfaces.

More than 2.5 million people are living with a hip replacement in the United States, and demand is expected to further increase due to an aging baby boomer population, higher rates of arthritis treatment and increasing demands for improved mobility15.

Stryker will showcase its latest technologies, including the Trident II Acetabular System, at the Academy meeting in New Orleans (booth #2451) from March 6-10, 2018.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.  More information is available at www.stryker.com.


1 Domb B, Redmond J, Louis S, Alden K, Daley R, LaReau J, et al. Accuracy of component positioning in 1980 total hip arthroplasties: a comparative analysis by surgical technique and mode of guidance. The Journal of Arthoplasty. 30(2015)22082218.
2 Australian Orthopaedic Association. National Joint Replacement Registry. Annual Report. AOA; 2017.
3 UK National Joint Registry, 2017 Report.
4 Naziri Q, et al. Excellent results of primary THA using a highly porous titanium cup. Orthopedics. 2013;36(4):390-394.
5 Ramappa M, et al. Early results of a new highly porous modular acetabular cup in revision arthroplasty. Hip Int.2009;19(3):239-244.
6 Capello WN, et. al. Arc-deposited hydroxyapatite-coated cups: results at four to seven years. Clin Orthop Relat Res. 2005;441:305-312.
7 Internal memo: Market Analysis of Poly Bearing Options – Trident II Versus Competitors. October 18, 2017.
8 Burroughs B, et al. Range of motion and stability in total hip arthroplasty with 28-, 32-, 38- and 44-mm Femoral Head Sizes In Vitro Study. J Arthroplasty. 2005;20(1):11-19.
9 Berry DJ, et al. Effect of femoral head diameter and operative approach on risk of dislocation after primary total hip arthroplasty. J Bone Joint Sur Am. 2005;87(11): 2456-2463.
10 Stryker R&D Technical Memo: Comparison of Tritanium Porous Surface to Cancellous Bone. A0027625
11 D’Antonio J, et al. Second-generation annealed highly crosslinked polyethylene has low wear at mean seven year follow-up. Surgical Technology International. 2014;25:219-26.
12 Jauregui J, et al. Dual mobility cups: an effective prosthesis in revision total hip arthroplasties for preventing dislocations. Hip Int. 2016 Jan-Feb;26(1):57-61.
13 Su E, et al. The role of constrained liners in total hip arthroplasty. Clin Orthop. 2004;420:122-129.
14 Dr. Beaver is a paid consultant of Stryker Orthopaedics. The opinions expressed by Dr. Beaver are those of Dr. Beaver and not necessarily those of Stryker. Individual experiences may vary.
15 Kremers, HM, Larson, DR, Crowson, CS, et al. Prevalence of total hip and knee replacement in the United StatesJ Bone Joint Sur Am. 2015;97:1386-97.

SOURCE Stryker

Related Links

http://www.stryker.com

New ATTUNE® Revision Knee System from DePuy Synthes Utilizes Proprietary Technologies to Address Broad Range of Complex Primary and Revision Procedures

NEW ORLEANSMarch 6, 2018 /PRNewswire/ — DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announced the US launch of the ATTUNE® Revision Knee System, to complement the ATTUNE Primary Knee System and provide surgeons with a comprehensive solution for knee replacement. The ATTUNE Revision Knee System is being introduced at the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans, LA.

While knee replacement is widely recognized as one of the most common and successful surgical procedures, approximately five percent of patients will require a revision surgery 10 years after the initial procedure 1,2 for a variety of reasons.  Revision surgeries can create complexities particularly in cases where large bone defects present reconstruction and fixation challenges. The ATTUNE Revision Knee System aims to address some of those challenges through improved kinematics, fixation and patient fit. With both fixed-bearing and rotating platform options, it is one of the most comprehensive revision knee systems available on the market today.

“The ATTUNE Revision Knee System provides the implant options I need to treat a variety of patient anatomies including more metaphyseal sleeve sizes, offset adaptors, stems and fixation choices,” said Dr. Douglas Dennis***, Orthopaedic Surgeon, Denver, CO. “The ATTUNE Revision Knee System incorporates the advantages of the ATTUNE Primary Knee System such as AOX™ Polyethylene, enhanced locking mechanisms and improved kinematics via the ATTUNE GRADIUS™ Curve condylar geometry.”

In a large, multi-center study, the ATTUNE Primary Knee System demonstrated improved outcomes across a broad range of Patient Reported Outcome Measures (PROMs) compared to certain existing knee brands at one-year minimum follow-up.3 The same technologies that helped deliver these outcomes are also incorporated in the ATTUNE Revision Knee System, helping to address overall patient satisfaction.

“The ATTUNE Revision Knee System introduces a new chapter in the ATTUNE Knee story,” said Rajit Kamal, Vice President and Global Platform Leader, Knees, DePuy Synthes. “With six years of successful clinical history and more than 575,000 ATTUNE Primary Knees implanted worldwide, the new ATTUNE Revision Knee System allows us to bring proprietary technologies of the ATTUNE Knee System to more patients around the world.”

The ATTUNE Revision Knee System is designed to work in harmony with the patient’s anatomy to deliver stability in motion during activities such as stair ascent or descent, walking uphill or downhill or getting up from a chair through:

  • ATTUNE GRADIUS Curve is designed to address the unnatural sliding of the femur on the tibia, to provide smooth motion and stability during everyday activities
  • GLIDERIGHT™ Articulation is designed to enable the ATTUNE Knee design to more accurately replicate the normal patello-femoral kinematics of the native knee

The ATTUNE Revision Knee System is now available in the US. For more information, please click here.

About the Johnson & Johnson Medical Devices Companies

The Johnson & Johnson Medical Devices Companies** have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopaedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services.

About DePuy Synthes

DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.

***Dr. Douglas Dennis is a consultant to DePuy Synthes Joint Reconstruction.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of a new product, the ATTUNE® Revision Knee System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; product efficacy or safety concerns resulting in product recalls or regulatory action; manufacturing difficulties and delays; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including under the captions “Item 1A. Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

1M. Khan, K. Osman, G. Green, F. S. Haddah (2016). The epidemiology of failure in total knee arthroplasty. The Bone & Joint Journal, 98-B (1 Suppl A), 105-12.
2Sharkey, Peter F., et al. “Why are total knee arthroplasties failing today – has anything changed after 10 years?” The Journal of Arthroplasty 29.9 (2014) 1774-1778.
3Hamilton W.G., Brenkel, I., Clatworthy, M., Dwyer, K., Himden, S., Lesko, J., Kantor, S.:  Early Outcomes with a New Primary TKA System vs. Contemporary TKA: Interim Results of Two Worldwide, Multi-Center Prospective Studies.  AAOS, San Diego, CaliforniaMarch 14-18, 2017, Poster 106. Other implants tested: SIGMA Knee (DePuy), NexGen® (Zimmer), Triathlon® (Stryker).

© DePuy Synthes 2018. All rights reserved.

DSUS/JRC/0218/2584

SOURCE DePuy Synthes

Photo: DePuy Synthes ATTUNE Revision Knee System / Courtesy of DePuy Synthes

Related Links

http://www.depuysynthes.com

New Q-FIX™ CURVED, Q-FIX MINI and SUTUREFIX CURVED All-Suture Anchor Systems help surgeons access challenging pathology while improving the quality of shoulder and hip repairs

LONDON, March 6, 2018 /PRNewswire/ — Smith & Nephew (NYSE: SNN, LSE: SN), the global medical technology business, is pleased to  announce the launch of Q-FIX CURVED, Q-FIX MINI and SUTUREFIX CURVED All-Suture Anchor systems adding to its growing Sports Medicine portfolio. Designed for procedures where space is limited and the anatomy can be difficult to access, the new SUTUREFIX CURVED, Q-FIX CURVED and MINI delivery systems are designed to aid in optimal suture anchor placement during drilling and insertion.

The SUTUREFIX CURVED and Q-FIX CURVED systems improve access and trajectory when drilling bone tunnels. Both systems optimize the curved geometry of the drill guide while also maximizing drilling accuracy. 1 The incorporation of both visual and tactile cues simplifies drill guide orientation for the surgeon and helps to indicate drilling trajectory.

The Company also introduced its Q-FIX MINI All-Suture Anchor, which reduces the tunnel drill depth and implant length to 17.1mm, making it the shortest all-suture anchor in its class.2

“The new Q-FIX CURVED drilling system and Q-FIX MINI represent another advancement by Smith & Nephew in soft tissue fixation,” said Felix H. “Buddy” Savoie III, MD, Chairman of Orthopaedic Surgery and Chief of Sports Medicine at Tulane University School of Medicine. “The curved drilling system improves access to the inferior glenoid while improving the trajectory of the drill bit, thereby reducing the risk of bicortical perforation. And the MINI anchor’s short drill depth improves patient safety, making it more useful in all applications, especially in small joint soft tissue fixation.”

“The unique tapered distal curve of the SUTUREFIX CURVED Drill Guide allows me to place these anchors anywhere that I would like along the acetabular rim,” said Dr. Marc J. Philippon of the Steadman Philippon Research Institute. “The active deployment of this all-suture anchor system greatly reduces displacement and the new curved guide has a better curvature and drilling trajectory than other curved systems on the market.”

“The Q-FIX MINI, Q-FIX CURVED and SUTUREFIX CURVED enable healthcare professionals to access challenging pathology like they have never been able to do before,” said Scott Schaffner, Senior Vice President Global Marketing, Smith & Nephew. “These new products highly complement our Sports Medicine range and we’re proud to offer them as part of our growing portfolio.”

Unlike other all-suture anchors that require the suture strands to be pulled back against the cortical bone in order to deploy them, Smith & Nephew’s Q-FIX and SUTUREFIX All-Suture Anchor platform uses active deployment3, which eliminates manual tensioning and makes deployment more reliable4, ultimately resulting in improved biomechanical performance among all-suture anchors.5,6,7

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

References:

1.    Data on file. Report P/N 15007031 Rev. A, Q-FIX Family Drill Deviation.
2.    Data on file. Report P/N 15006934 Rev. A, SUTUREFIX And Q-FIX Family Geometric Claims, page 11.
3.    Douglass NP, Behn AW, Safran MR. Cyclic and Load to Failure Properties of All-Suture Anchors in Synthetic Acetabular and Glenoid Cancellous Bone. Arthroscopy. 2017 May;33(5):977-985.e5. doi: 10.1016/j.arthro.2016.11.022. Epub 2017 Jan 26.
4.    Byrd, JWT, Jones, KS, Loring, CL, Sparks, SL. Acetabular All-Suture Anchor for Labral Repair: Incidence of Intraoperative Failure due to Pullout Arthroscopy: The Journal of Arthroscopic & Related Surgery Available online 17 January 2018. doi 10.1016/j.arthro.2017.09.049.
5.    Erickson J, Chiarappa F, Haskel J, Rice J, Hyatt A, Monica J, Dhawan A. Biomechanical Comparison of a First- and a Second-Generation All-Soft Suture Glenoid Anchor. The Orthopaedic Journal of Sports Medicine, 5(7), 2017. doi.org/10.1177/2325967117717010.
6.    Barber AB, Herbert MA. All-Suture Anchors: Biomechanical Analysis of Pullout Strength, Displacement, and Failure Mode. Arthroscopy.2017 Jun;33(6):1113-1121. doi: 10.1016/j.arthro.2016.09.031. Epub 2016 Dec 22.
7.    Nagra NS, Zargar N, Smith RD, Carr AJ. Mechanical Properties of All-suture Anchors for Rotator Cuff Repair.Bone Joint Res. 2017 Feb;6(2):82-89. doi: 10.1302/2046-3758.62.BJR-2016-0225.R1.

 

SOURCE Smith & Nephew

Related Links

http://www.smith-nephew.com

Corin Group Launches Trinity™ Dual Mobility System for Hip Replacement at AAOS 2018 Annual Meeting

NEW ORLEANSMarch 6, 2018 /PRNewswire/ — Corin, a global orthopaedic manufacturer and leader in functional implant positioning, today announced the launch of the Trinity™ Dual Mobility System featuring new implant technology designed to improve range of motion and reduce the risk for instability and dislocation after primary or revision hip replacement. The announcement was made here at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting.

 

Medacta Emphasizes Flexibility for Surgeons and Patients Alike With Launch of MOTO Medial Partial Knee, Medacta Shoulder System and MasterLoc Lateralized Plus at AAOS

March 06, 2018

NEW ORLEANS–(BUSINESS WIRE)–Medacta® International, the privately held family-owned global leader in the design of innovative joint replacement and spine surgery products, today launched its new MOTO™ Medial Partial Knee System, Medacta Shoulder System and a third offset option for its MasterLoc™ Hip System at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, held March 6-10 in New Orleans, Louisiana. The company will be showcasing these products at Booth #6329 and will also be co-sponsoring a guest reception honoring Italy’s contributions to orthopedic innovation.

“Medacta remains focused on delivering new and innovative orthopedic solutions paired with hands-on support, solid education programs and expert mentorship to help surgeons more efficiently and effectively meet their patients’ needs,” said Francesco Siccardi, executive vice president of Medacta International. “With our MOTO Knee, Shoulder System and MasterLoc LAT PLUS, we’re making it easier for surgeons to treat complex cases or patients with hard-to-match anatomies and optimizing procedures for the outpatient setting to meet growing demand.”

MOTO Partial Knee System: Enabling Superior Fit, Balance and Alignment

Medacta’s MOTO Medial Partial Knee System is a compartment-specific, fixed-bearing solution for partial knee replacement, or unicompartmental knee arthroplasty (UKA), in which only a portion of the knee is resurfaced. Partial knee replacements are rapidly becoming a common choice for orthopedic surgeons seeking to offer patients the option of pain relief in the outpatient setting. With patient demand on the rise, Medacta designed the MOTO System and detailed education platform to simplify common procedural challenges and make partial knee cases easier to perform in an outpatient setting.

The MOTO implants are designed for each specific compartment using an anthropometric database of more than 45,000 CT and MRI knee scans to optimize anatomic coverage, contours, size range and precise fit. Perhaps the most distinguishing feature of MOTO is the instrumentation that allows for precise bone resections to balance knee flexion-extension gap mismatch, while maintaining slight alignment under-correction.

“There was still much to be improved in partial knee arthroplasty,” said J. Mandume Kerina, MD, founder of Unova Health Clinic in Lady Lake, Florida and co-designer of the MOTO Partial Knee, who has been performing outpatient knee replacements for more than a decade. “Based on registry data and results, the MOTO Partial Knee was designed following the fixed-bearing, round-on-flat design, but improves upon the options and flexibility built into the system. The result – an anatomic design, optimized sizing options, logical instrumentation and a versatile surgical technique – gives surgeons more control than before and better addresses challenging patient anatomies.”

In keeping with its commitment to surgeon education and training, Medacta created a unique education program around the MOTO Partial Knee that provides top-level medical education and continuous support to ensure surgeons transitioning to using the implant have adequate support and are able to deliver the best possible outcomes to their patients.

Medacta Shoulder System: Featuring Anatomic and Reverse Options for Complex Cases

The Medacta Shoulder System is a modular solution designed to address the unique challenges around complex shoulder arthritis. Developed by an international team of expert surgeons, the platform offers both Anatomic and Reverse Shoulders to deliver the modularity and compatibility demanded by today’s marketplace. Its unparalleled implant selection allows for an anatomic fit for a wide range of pathologies, with other options including wide-ranging sizes, adjustable offsets and other innovative configurations.

Medacta’s first foray in the shoulder surgery market, the platform was unveiled in February 2017 following its first ever surgery in Europe, while its first U.S. surgery took place in the fall of 2017. The system is now available for surgeons throughout the United States and Europe.

MasterLoc LAT PLUS: Providing Unmatched Offset Range for Optimal Restoration

With the addition of the LAT PLUS, Medacta’s MasterLoc Hip System is the only flat-tapered wedge stem for total hip replacement with a unique progressive triple offset, giving surgeons more options to better suit their patients’ needs without impacting leg length. Adding to the MasterLoc’s existing standard offset (STD) and lateralized version (LAT), which adds an extra six millimeters of femoral offset to the STD, the LAT PLUS offers another five millimeters of offset to help surgeons enhance component stability.

The MasterLoc Hip System was introduced in November 2016 as another addition to Medacta’s cementless implant portfolio. The MasterLoc features Medacta’s Mectagrip plasma-sprayed titanium coating, designed to enhance initial fixation with its high coefficient of friction and the potential long-term stability inherent to titanium plasma-sprayed devices.

Guest Nation Reception at AAOS: Honoring Italy’s Contributions

Medacta International is also co-sponsoring the 2018 Guest Nation Reception honoring Italian orthopedic professional attendees at AAOS. The Boards of Directors of the Italian Society of Orthopaedics and Traumatology (SIOT) and of AAOS will be present among more than 200 guests. The reception will take place on Friday, March 9, 2018 from 6:30-8:30 p.m. Eastern.

About Medacta International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

Contacts

For Medacta International
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com

Materialise to Launch TRUMATCH® Personalized Solutions Shoulder System

March 06, 2018

PLYMOUTH, Mich.–(BUSINESS WIRE)–Materialise NV (Nasdaq:MTLS) launched a shoulder planner for surgeons with the possibility to plan shoulder arthroplasty cases and order patient-specific shoulder guides, in collaboration with DePuy Synthes. The TRUMATCH® Personalized Solutions Shoulder System, revealed at the AAOS Annual Meeting in New Orleans, marks a further extension of Materialise’s longstanding collaboration with DePuy Synthes, who will distribute the solution in the United States, Canada, Australia, New Zealand and Europe.

The TRUMATCH® Personalized Solutions Shoulder System will help orthopaedic surgeons prepare for shoulder arthroplasty surgery, specifically addressing Reverse Shoulder Arthroplasty (RSA) and Anatomic Total Shoulder Arthroplasty (TSA) operations. It offers surgeons an all-in-one, web-based platform that allows them to better plan and prepare for these operations as well as order patient specific 3D printed surgical guides.

RSA and TSA operations present unique challenges, with limited visibility as the result of the small incision, the Glenoid cavity being deep in the surgical window and the lack of reliable landmarks. However, precise alignment is required, not just because of limited bone stock, but because of its impact on overall screw length and fixation (with RSA) and the occurrence of peg perforation (with TSA).

Compared to using 2D images to diagnose and perform a shoulder arthroplasty, pre-surgical planning lets surgeons know what to expect upfront, working in three dimensions. With 3D virtual pre-surgical planning, implant positioning is done within a stable reference frame, linked to the entire scapula, using reliable landmarks that are not subject to case specific wear patterns. This allows the surgeon to be more precise in the alignment of the implant and screw positioning, improving overall fixation. The measurement, viewing and implant positioning features of the TRUMATCH® Personalized Solutions Shoulder System helps surgeons make better informed, clinical decisions before, rather than during surgery, taking control of an important step for a more desired outcome. This increased pre-operative preparedness gives the surgeon and the team more confidence and control during surgery.

As a result of the pre-operative planning, surgeons may decide to execute the surgery with personalized guides if it’s believed that conventional instruments or standard guides are less appropriate because of glenoid deformities. The TRUMATCH® Personalized Solutions Shoulder System also allows surgeons to order patient specific 3D printed shoulder guides within the same platform.

“3D planning is gaining popularity with orthopaedic surgeons performing shoulder operations,” said Wilfried Vancraen, Founder and CEO of Materialise. “Together with our strategic partners like DePuy Synthes, we are continually working to improve surgical planning processes for a range of operations. We are proud that this expanded collaboration will empower even more orthopaedic surgeons to discover the benefits of online planning and 3D-printed, patient-specific surgical guides.”

Materialise is exhibiting during the annual meeting for the American Academy of Orthopaedic Surgeons, March 6-10, 2018 in New Orleans. The company hosts live software demonstrations and expert talks on booth #3729 as well as a lunchtime presentation on March 7 in the Technology Theatre. Learn more at http://www.materialise.com/en/medical/orthopaedic-surgeons-meeting-2018.

About Materialise
Materialise incorporates 27 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.

About Materialise’s Medical Division
Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific care. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, forms the foundation of certified Medical 3D Printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: medical.materialise.com.

Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

Contacts

Press Contacts:
Materialise
Virginia Goble
Vice President Marketing-North America
Mobile: (248) 921-5500
Email: virginia.goble@materialise.com or press@materialise.com
Twitter: @MaterialiseNV
Visit: www.materialise.com
or
Franco
Megan Peterson
Mobile: 248.330.9807
Email: peterson@franco.com

Photo credit: Materialise

CellRight Technologies Signs Multi-Year Distribution Agreement With Arthrex, Inc.

March 06, 2018

SAN ANTONIO–(BUSINESS WIRE)–Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) the regenerative medical devices company today announces subsidiary CellRight Technologies (“CellRight”) has signed a long-term, multi-year distribution agreement with Arthrex, Inc., a premier innovator of orthopaedic surgical solutions.

CellRight, which produces industry leading verified osteobiologics for use in orthopaedic, spine and foot and ankle procedures, enhances the healing opportunities of defects caused by trauma and disease.

The multi-year commitment will give surgeons access to verified osteobiologics and advanced surgical instrumentation and techniques to help influence better patient outcomes.

“This long-term distribution agreement will allow physicans and patients better access to CellRight’s innovative orthobiologics through the Arthrex network,” said Jesus Hernandez, CEO for CellRight Technologies. Our shared vision of offering surgeons total solutions which can positively impact patient outcomes solidifies the decision of both companies to work together.”

Steve Couldwell, CEO Tissue Regenix Group plc commented: “This is a flagship distribution agreement for CellRight and the wider Tissue Regenix Group. It highlights the value of strategic partnerships with prestigious companies in this space. We look forward to working with Arthrex to bring the CellRight product portfolio to an extended network of healthcare professionals.”

CellRight Technologies and TRX Orthopedics, will be exhibiting at the American Academy of Orthopaedic Surgeons in New Orleans, March 7-10 and can be found at booth #5413.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company’s patented decellularisation (‘dCELL®‘) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States – ‘Tissue Regenix Wound Care Inc.’, rebranded TRX BioSurgery in February 2018. January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight’s human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

Contacts

Tissue Regenix Group plc
Caitlin Pearson Head of Communications
Tel: (+44) 330 430 3073 / 07920272 441
or
FTI Consulting
Brett Pollard / Mo Noonan/ Rob Winder
Tel: 0203 727 1000